Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

SEATTLE, Feb. 17, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the 2011 Genitourinary Cancers Symposium annual meeting in Orlando, Florida.

  • "Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies," abstract #139.  Reception and General Poster Session B: Prostate Cancer (A33) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011.
  • "Characterization of Antigen-Specific T cell Activation and Cytokine Expression Induced by Sipuleucel-T," abstract #155. Reception and General Poster Session B: Prostate Cancer (A49) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011.

Abstract #139: Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies

This exploratory analysis evaluated the survival of patients who were randomized to the control arm in the three metastatic castrate resistant prostate cancer PROVENGE® (sipuleucel-T) Phase 3 clinical trials (D9901, D9902A, D9902B).  Control used in the trial was non-activated autologous peripheral blood mononuclear cells.  Patients in these trials who were randomized to receive control had the opportunity to participate in an open label Phase 2 protocol that allowed them to receive APC8015F, an investigational autologous cellular immunotherapy made from cryopreserved cells at the time of control generation.

Results from the exploratory analysis show patients treated with APC8015F (n=155) after their disease progressed had improved survival relative to the patients not treated in the control arm (n=61).  Following disease progression, the median survival of patients treated with APC8015F was 20.0 months compared to 9.8 months for control patient
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... Metabolomx, a diagnostic company focused on breath analysis ... was awarded a Small Business Innovation Research (SBIR) contract ... combined Phase I/II Fast-Track contract will support the research ... lung cancer. Metabolomx, proprietary technology is designed ...
... N.J., Oct. 21, 2011  Palatin Technologies, Inc. (NYSE Amex: ... the 10th Annual BIO Investor Forum on Wednesday, October 26, ... Industry Organization (BIO), the 10th Annual BIO Investor Forum will ... Francisco, CA.  Carl Spana, Ph.D., President and ...
... Reserve University have made an electrochemical cell that uses ... of metal. The technology may open new pathways ... hydrogen fuel and synthesizing nanomaterials and polymers. A ... online edition of the Journal of the American ...
Cached Biology Technology:Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer 2Electrochemistry controlled with a plasma electrode 2
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... 14, 2011 DERMALOG Identification Systems GmbH ... new world record in the identification of fingerprints. The ... capable of correctly identifying the ten fingerprints of one ... than 129 million fingerprints. The renowned international SGS INSTITUT ...
... An estimated 300,000 people in North America are afflicted ... of motor control. Patients with generalized dystonia grapple with ... turning in awkward, sometimes painful postures. Although cognition, intelligence ... have a devastating impact on quality of life, as ...
... Scientists are another step closer to understanding what drives ... inside tumors that can slow their own growth. ... a journal of the American Association for Cancer Research, ... division of experimental medicine at the National Academy of ...
Cached Biology News:World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 2World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 3University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
... Light Antifade Kit is an aqueous-based mounting ... fluorescent dyes. This formulation of antifade minimizes ... Cascade Blue fluorophores that is often seen ... is available with the blue-fluorescent nucleic acid ...
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
Biology Products: